S. Kim

发表

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

D. Heo, C. Suh, J. H. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Smit, E. Felip, 2012 .

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin-naive patients with extensive-disease small cell lung cancer (Cancer (2009) 116, (132-136))

Dong Han Lee, M. Ahn, C. Suh, 2010 .

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

P. Jänne, D. Planchard, S. Kim, 2021, ESMO open.

Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma

O. Noh, S. Kim, Y. Oh, 2018, Clinical and Translational Oncology.

Coinfection with Respiratory Pathogens in COVID-19 in Korea

Y. Kim, S. Kim, K. Roh, 2020, medRxiv.

Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.

M. Ahn, E. Choi, S-H. Jung, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of concurrent thoracic radiotherapy with either fi rst-or third-cycle chemotherapy for limited-disease small-cell lung cancer †

M. Ahn, E. Choi, S-H. Jung, 2013 .

Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.

G. Scagliotti, Y. Ichinose, J. Kim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma.

Y. Matsuno, Y. Kagami, K. Tobinai, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Dae-Ho Lee, C. Suh, H. T. Kim, 2012, Lung Cancer.

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

K. Kim, S. Kim, S. Park, 2007, Journal of Clinical Pathology.

Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

M. Ahn, H. Saka, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019, Annals of Oncology.

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

S. Ou, M. Ahn, N. Segal, 2016 .

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

K. O'Byrne, F. Nathan, K. Lee, 2022, ESMO open.

NK and NK‐like T‐cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status

E. Cho, H-K. Chang, H. Ree, 2004, Histopathology.

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

M. Ahn, E. Cho, S. Shreeve, 2021 .

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases

J. Boyd, P. Borgen, S. Kim, 2005, Journal of Medical Genetics.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

A. Dingemans, J. Mazières, M. Schuler, 2022, Annals of Oncology.

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O

Haiyi Jiang, D. Gibbons, L. Chow, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.

D. Lee, S. Kim, J. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

Dong-Wan Kim, D. Heo, S. Shin, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Caveolin‐1 is down‐regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast

S. Kim, S. Park, J. E. Kim, 2005, Histopathology.

OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

M. Tsuboi, R. Herbst, Yi-long Wu, 2021 .

LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

M. Tsuboi, Jie He, R. Herbst, 2020 .

An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer

Jae Hyun Kim, Y. Kim, E. Kang, 2011, British Journal of Cancer.